Tresivac Vaccination in Chennai

Tresivac – Serum International Institute

Indication and Usage –

• MMR is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.

Dosage and Administration –

• For subcutaneous use only.
• The first dose is administered at 12 to 15 months of age. A second dose is administered at 4 to 6 years of age.
• The second dose may be administered prior to 4 years of age, provided that there is a minimum interval of one month between the doses of measles, mumps and rubella virus vaccine.
• Children who received an initial dose of measles, mumps and rubella vaccine prior to their first birthday should receive additional doses of vaccine at 12-15 months of age and at 4-6 years of age to complete the vaccination series.

Contraindications –

• Hypersensitivity –

1. Do not administer MMR vaccine to individuals with a history of hypersensitivity to any component of the vaccine or who have experienced a hypersensitivity reaction following administration of a previous dose of MMR vaccine or any other measles, mumps and rubella containing vaccine.
2. Do not administer MMR vaccine to individuals with a history of anaphylaxis to neomycin.

• Immunosuppression –

1. Do not administer MMR vaccine to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy.
2. Measles inclusion body encephalitis {4} (MIBE), pneumonitis {5} and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with measles-containing vaccine.
3. In this population, disseminated mumps and rubella vaccine virus infection have also been reported.

• Moderate or Severe Febrile Illness –

1. Do not administer M-M-R II vaccine to individuals with an active febrile illness with fever >101.3°F (>38.5°C).

• Active Untreated Tuberculosis –

1. Do not administer MMR vaccine to individuals with active untreated tuberculosis (TB).

• Pregnancy –

1. Do not administer MMR vaccine to individuals who are Pregnant or who are planning on becoming pregnant within next month.

Adverse reactions –

The following adverse reactions include those identified during clinical trials or reported during post approval use of MMR vaccine or its individual components.

• Body as a Whole - Panniculitis; atypical measles; fever; syncope; headache; dizziness; malaise; irritability.
• Cardiovascular System -
• Digestive System - Pancreatitis diarrhea; vomiting; parotitis; nausea.

Hematologic and Lymphatic Systems -Thrombocytopenia; purpura; regional lymphadenopathy; leukocytosis.

• Immune System - Anaphylaxis, anaphylactoid reactions, angioedema (including peripheral or facial edema) and bronchial spasm.
• Musculoskeletal System- Arthritis; arthralgia; myalgia.
• Nervous SystemEncephalitis encephalopathy; measles inclusion body encephalitis (MIBE) subacute sclerosing panencephalitis (SSPE); Guillain-Barré Syndrome (GBS); acute disseminated encephalomyelitis (ADEM); transverse myelitis; febrile convulsions; afebrile convulsions or seizures; ataxia; polyneuritis; polyneuropathy; ocular palsies; paresthesia.
• Respiratory System Pneumonia; pneumonitis; sore throat; cough; rhinitis.

Drug interactions and other interactions –

• Corticosteroids and Immunosuppressive Drugs

MMR vaccine should not be administered to individuals receiving immunosuppressive therapy, including high dose corticosteroids. Vaccination with MMR vaccine can result in disseminated disease due to measles vaccine in individuals on immunosuppressive drugs.

• Immune Globulins and Transfusions

Administration of immune globulins and other blood products concurrently with MMR vaccine may interfere with the expected immune response. The ACIP has specific recommendations for intervals between administration of antibody containing products and live virus vaccines.

• Tuberculin Skin Testing

It has been reported that live attenuated measles, mumps and rubella virus vaccines given individually may result in a temporary depression of tuberculin skin sensitivity. Therefore, if a tuberculin skin test with tuberculin purified protein derivative is to be done, it should be administered before, simultaneously with, or at least 4 to 6 weeks after vaccination with MMR vaccine.

• Use with Other Live Viral Vaccines

MMR vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, MMR vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.